Guardant faces a material and growing financial liability from this ruling, with no relief granted on appeal-ripe issues. The ongoing 6% royalty on its core sequencing products (Guardant360, Companion, Explore) will persistently pressure margins. Monitor Guardant's appeal to the Federal Circuit and any USPTO reexamination outcomes that could narrow claim scope; the court already found the reexamination statements insufficient to change the judgment. Investors should price in at minimum the base $83.4M award plus accumulating ongoing royalties and interest.
Price Chart
Executive Summary
The District of Delaware denied Guardant Health's post-trial motions in a patent infringement case brought by TwinStrand Biosciences and UW. The jury's 2023 verdict of willful infringement on two patents covering DNA sequencing technology stands, with $83.4M in damages based on a 6% royalty on $1.39B revenue base. The court denied enhanced damages and attorney fees but granted ongoing royalties at the same 6% rate plus supplemental damages and pre/post-judgment interest. Guardant's products and services (including Guardant360, Companion, Explore) were found to infringe.
Court Ruling Details
Key Facts
- Jury awarded $83.4M in reasonable royalty damages (6% on $1.39B base including $106M services revenue) for willful infringement of claims on patented duplex consensus sequencing technology
- Court denied Guardant's motions for JMOL, new trial, and Rule 60(b) relief on all grounds — infringement findings across products (Guardant360) and services (Companion, Explore) are upheld
- Ongoing royalty set at 6% for adjudicated products post-verdict, plus supplemental damages at 6% for sales July 2023–Feb 2024, and pre-judgment interest at prime rate compounded quarterly
- Court declined to enhance damages under Read factors — case was close, no egregious litigation misconduct or concealment — but willfulness verdict was supported by evidence
- Guardant's Rule 60(b) motion based on USPTO reexamination statements was denied — statements did not constitute clear disclaimer of claim scope
Financial Impact
$83.4M jury award plus ongoing 6% royalty on continuing infringing sales, supplemental damages, and pre/post-judgment interest — total likely exceeds $100M over time
Risk Factors
- Appeal to Federal Circuit likely takes 1–2 years; risk of affirmance maintains or expands liability
- Ongoing royalty stream accumulates at 6% on infringing product revenue with no cap or end date unless settlement reached or patents expire
- Precedent for other patent holders asserting related sequencing patents against Guardant's technology stack
- Potential for injunction on future sales if ongoing royalty regime is challenged or if reexamination narrows but does not eliminate claims
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1lcqsqc2-GH |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $163.18 $177.16 | ▲ +8.57% | ▲ +7.25% | $177.80 (+8.96%) |
Aug 13, 2026 7w ago | Insider Cluster | $157.21 $167.84 | ▲ +6.76% | ▲ +8.75% | $177.80 (+13.10%) |
Aug 13, 2026 7w ago | Insider Cluster | $157.21 $167.84 | ▲ +6.76% | ▲ +8.75% | $177.80 (+13.10%) |
Aug 11, 2026 7w ago | Insider Cluster | $165.11 $159.03 | ▼ −3.68% | ▼ −1.78% | $177.80 (+7.69%) |
Aug 11, 2026 7w ago | Insider Cluster | $165.11 $159.03 | ▼ −3.68% | ▼ −1.78% | $177.80 (+7.69%) |
Aug 6, 2026 8w ago | Insider Cluster | $168.48 $161.41 | ▼ −4.20% | ▼ −3.80% | $177.80 (+5.53%) |
Jul 30, 2026 9w ago | S-3ASR | $161.99 $161.49 | ▼ −0.31% | ▼ −3.29% | $177.80 (+9.76%) |
Jun 30, 2026 13w ago | Insider Cluster | $170.77 $144.07 | ▼ −15.64% | ▼ −13.45% | $177.80 (+4.12%) |
Jun 22, 2026 14w ago | 144 | $130.83 $148.07 | ▲ +13.18% | ▲ +12.02% | $177.80 (+35.90%) |
Jun 16, 2026 15w ago | Court Ruling | $127.34 $160.11 | ▼ −25.73% | ▼ −25.53% | $177.80 (−39.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access